Written questions by Smith.

Whether the scheduled January meeting of the cross-government working group on how best to reduce barriers to clinical research with Schedule 1 drugs took place, and whether minutes will be available on public record.

A meeting of the cross-government working group on reducing barriers to research with Schedule 1 drugs took place on 23 January. The working group is comprised of officials from the relevant government departments and regulatory bodies. The group’s role is the formulation of policy. As such its considerations are not agreed government policy and we have no plans to publish them. The Government remains committed to implementing the recommendations of the Advisory Council on the Misuse of Drugs on reducing barriers to research with Schedule 1 drugs and we will publish our plans in this area in due course.

If she will list the meetings scheduled for the working group on any new issues involving research with controlled drugs during the next six months.

On 16 July, the Government responded to recommendations from the Advisory Council on the Misuse of Drugs (‘ACMD’) on how best to reduce barriers to clinical research with Schedule 1 drugs. The Government committed to set up a cross-government working group of officials to assist with delivery of those recommendations.The group had its first meeting in September, followed by a series of bilateral discussions between Home Office officials and the organisations represented on the working group. The next meeting is planned for January. Alongside the working group, officials have ongoing engagement with relevant officials in wider departments and agencies, and with businesses, representative organisations and researchers who are likely to benefit from the proposals. Officials have also explored with international counterparts the provisions for research with controlled drugs in their jurisdictions.

How many meetings have been held of the cross-government officials working group on research with controlled drugs.

On 16 July, the Government responded to recommendations from the Advisory Council on the Misuse of Drugs (‘ACMD’) on how best to reduce barriers to clinical research with Schedule 1 drugs. The Government committed to set up a cross-government working group of officials to assist with delivery of those recommendations.The group had its first meeting in September, followed by a series of bilateral discussions between Home Office officials and the organisations represented on the working group. The next meeting is planned for January. Alongside the working group, officials have ongoing engagement with relevant officials in wider departments and agencies, and with businesses, representative organisations and researchers who are likely to benefit from the proposals. Officials have also explored with international counterparts the provisions for research with controlled drugs in their jurisdictions.